Crystawash(R) Extend distribution in UAE, Kuwait, Oman and Ke

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





12 April 2021


Crystawash
®
Extend distribution in UAE, Kuwait, Oman and Kenya.
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed agreements
to distribute its long-acting hand sanitiser Crystawash
®
Extend in the United Arab
Emirates, Kuwait, Oman and Kenya.
In a move that reflects the growing importance of Asian markets to AFT, the company
also announces it has appointed a Business Manager for Promoted Products in Asia
based out of Hong Kong.
Crystawash Extend
The Crystawash Extend agreements are with Germany’s Pharma Bavaria International
GmbH, which has well established distribution networks in various countries in the
Middle East and Africa.
AFT developed Crystawash Extend, a long-lasting hand sanitiser, to overcome the
shortcomings of traditional alcohol-based sanitisers, which need to be applied
repeatedly to provide long-lasting protection.
The product, which has been found by independent laboratories to kill 99.99% of
germs on immediate contact and display 24-hour residual efficacy against germs
evidenced by testing on synthetic skin
1,2,3
, was launched in Australia and New Zealand
earlier this year.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are pleased
with the new deal for Crystawash Extend with Pharma Bavaria. It demonstrates how
we can leverage our international networks of partnerships to build distribution of our
unique products.
“With the outbreak of the Covid-19 pandemic, the world has seen a surge in demand
for hand sanitiser. While there may be some moderation of demand as the pandemic
is brought under control, we believe the pandemic is also entrenching new standards
of public health and personal hygiene practices that include the regular use of hand
sanitisers.
“Crystawash Extend meets this demand and does so in a way that is superior to
existing technologies. It is great example of AFT working to deliver on its mission to
improve global health outcomes.”

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

AFT is targeting sales of Crystawash Extend in countries covered by this new distribution
agreement to commence in the current financial year.

Building AFT’s Presence in Asia
AFT has appointed Lorraine Corr-Poppleton as the company’s Asia Business Manager,
Promoted Products, based in Hong Kong to spearhead the company’s presence in
the region. This will help serve our customers and partners in the seven territories in Asia
where we have licensing and distribution agreements in addition to our own
operations in Singapore, Malaysia and Hong Kong.
It will also help AFT to strengthen is relationships and partnerships in mainland China
where we are seeking regulatory approval for a number of products and where we
launched our online TMall (www.tmall.com
) presence last year.

“Lorraine has spent the last six years working throughout the region developing and
growing consumer products, it is great to have her join the AFT team and to benefit
from the relationships she enjoys in the region,” Dr Atkinson said.
For and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial
Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development programme forms the basis of its

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.
About Pharma Bavaria International GmbH
Pharma Bavaria International GmbH operates in more than 45 countries. With a strong
focus on growth regions such as the Middle East, Africa, South-East Asia, CIS countries
and other emerging economies Pharma Bavaria’s portfolio of prescription medicines
includes anti-infectives, analgesic/anti-inflammatory, flu and cold, gastroenterology,
oncology, cardiology and women’s healthcare areas.

References
1. VITRO-SKIN®; Florida Suncare Testing, Inc. IMS Division. https://ims-usa.com/vitro-
skin-substrates/vitro-skin/
2. AFT Pharmaceuticals/AsureQuality Laboratory Services, New Zealand
microbiological effectiveness study evaluating residual killing activity against transient
microbial skin flora on synthetic skin.
3. Time Kill Test conducted by Eurofins BioPharma Product Testing, Australia; Protocol:
TMD-110, EN 13727